Valbonne, France, May 28, 2018, 5.45pm CEST
TxCell SA (FR0010127662 – TXCL), a developer of cellular immunotherapies based on regulatory T cells (Tregs) for inflammation, autoimmunity and transplantation, today announces it will present its latest manufacturing developments at the 3rd Annual Bioprocessing of Advanced Cellular Therapies Congress to be held in Frankfurt, Germany, on May 29-30, 2018.
The purpose of this conference is to address the challenges of cell and gene therapy manufacturing processes, including safety, quality, logistics and regulatory hurdles. The implementation of automated, highly validated protocols and tools, giving these therapies the best chance of success, will also be discussed.
Pierre Heimendinger, PhD, VP Pharmaceutical Development of TxCell, will join a panel to discuss industry regulatory considerations, entitled: “Need for Standard Regulations – What are Companies Thinking?” (May 29, 11.35 am CEST). He will also present TxCell’s latest manufacturing achievements in a presentation entitled « Development of First Manufacturing Process to Produce CAR-Treg Cells for Clinical Use » (May 29, 4 pm CEST).